Cortagen (AEDP)
Also known as Cortagen · AEDP · Ala-Glu-Asp-Pro · cortical bioregulator
New
Reconstitution & dosing guide
20 mg vial — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only20mg x 10 vials
Cortagen · Not in current stock
$50 / vial
Prices per vial · Research use only · Not medical advice.
Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed as a cerebral-cortex-targeted short peptide for neuroprotection and cortical gene regulation research.
How to picture it
Same bioregulator philosophy, different address: cortical and cognitive-aging pathways. Picture a short signal that participates in how brain tissue manages stress and gene expression under age-related load — a precision note for neural maintenance rather than broad stimulation.
Research focus & benefits
- Cortical bioregulator research interest
- Cognitive-aging pathway studies
- Brain-directed short-peptide literature
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Cortagen is the synthetic cortex-focused member of the Khavinson ultrashort peptide family, reverse-engineered from cortical tissue extracts (related conceptually to Cortexin). Preclinical work emphasizes nerve regeneration, cortical gene-expression shifts, and neuroprotection under hypoxic or traumatic conditions. Clinical track record largely belongs to larger polypeptide extracts rather than the pure tetrapeptide.
Mechanism
Proposed direct chromatin/DNA interaction in cortical neurons with tissue-selective transcriptional modulation. Shares Ala-Glu-Asp core with Epitalon; proline C-terminus is associated with structural stability. Microarray work from the originating group reported differential expression of dozens to ~100+ genes after exposure.
Research uses
- Sciatic nerve regeneration models (improved conduction velocity reports)
- Cortical explant growth stimulation
- Neuroprotection in ischemia/hypoxia models
- Post-injury recovery adjunct research (extract literature)
Research dosing notes
Cyclic multi-day bioregulator protocols in source literature. No Western clinical dosing standard.
Half-life / kinetics
Short plasma half-life (ultrashort peptide)
Common research routes
Reported considerations
- Limited independent safety data
- Unknown CNS drug interactions
Contraindications / cautions
- Acute stroke — emergency care first
- Pregnancy
- Do not replace neurologic standard of care
Common research stacks
- Pinealon
- Epitalon
- Semax
- P21
Legal / access note
Research bioregulator; not an approved nootropic or stroke drug in the US.